Nasdaq
$8.23▲ 3.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $14.7MShares out 1.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.16After-hours26.10.17 06:204Ownership#●●●
Akari Therapeutics Plc
Insider Raymond Prudo-Chlebosz of Akari Therapeutics Plc reported a change in beneficial ownership of securities as of August 18, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$8.23+3.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 06:204Ownership
Akari Therapeutics Plc
Reporting person Huh Hoyoung filed a statement of changes in beneficial ownership of securities for Akari Therapeutics Plc, effective August 18, 2026. This filing serves as a standard disclosure regarding insider equity transactions.…more
$8.23+3.46%vs prev closeView filingShare - 10.16After-hours26.10.17 06:204Ownership
Akari Therapeutics Plc
Insider Sandip I. Patel of Akari Therapeutics Plc reported his beneficial ownership of securities as of August 18, 2026. This filing serves as a disclosure of changes in insider holdings via Form 4.…more
$8.23+3.46%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 22:20#●●●#●●●#●●●
Akari Therapeutics Outlines ADC Payload Strategy and Clinical Roadmap
Akari Therapeutics detailed its strategy for its proprietary PH1 payload and confirmed plans to initiate Phase 1 clinical trials by mid-2027. The announcement focuses on the company's technological vision and execution priorities rather than immediate clinical results.…more
$8.23+3.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 22:01
●●●●●●●● ●●●●● ●●●●●●
Akari Therapeutics has appointed oncology and ADC expert Vatnak Vat-Ho as its new Chief Business Officer. The appointment aims to strengthen the company's leadership team to drive strategic growth and future partnerships.…more
$8.23+3.46%vs prev close - 10.1Pre-market26.10.01 21:26
●●●●●●●● ●●●●● ●●●●●●
Akari Therapeutics has filed a new patent application to expand its intellectual property portfolio concerning its novel RNA splicing-modulating payload and ADC technology. This move aims to strengthen the company's proprietary position in the oncology biotechnology sector.…more
$8.23+3.46%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report